Vir Biotechnology Inc (Vir) is a biotechnology company which carries out the development of therapeutic products to prevent and treat serious infectious diseases. It develops treatments for viral and bacterial diseases and induce protective and therapeutic immune responses. The company includes in multi-program, multi-platform approach. Vir focuses on chronic infectious diseases including hepatitis B, tuberculosis, HIV; respiratory diseases, including influenza, respiratory syncytial virus (RSV) and metapneumovirus (MPV), healthcare-acquired infections. It has operations in Portland, Oregon, Boston, Massachusetts, Bellinzona, Switzerland. Vir is headquartered in San Francisco, California, the US.
Headquarters
United States of America
Address
1800 Owens Street, Suite 900, San Francisco, California, 94158
Website
www.vir.bio
Telephone
1 415 9064324
No of Employees
587
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
VIR (NASD)
Revenue (2022)
$86.2M
-94.7%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-219.2%
(2022 vs 2021)
Market Cap*
$1.2B
Net Profit Margin (2022)
XYZ
-2,335.9%
(2022 vs 2021)
* As of and is in US$
Vir Biotechnology Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Covid 19: |
| VIR-7831 (Early treatment – ambulatory) |
| VIR-7831 (Prophylaxis) |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In February, the company terminated its agreement with GSK to research, develop and leverage the biotech’s monoclonal antibodies for the prevention, treatment, or prophylaxis of the influenza virus. |
| 2023 | Contracts/Agreements | In February, the company amended its research partnership with GSK to develop next-generation COVID-19 therapies. |
| 2022 | Official Trials/Tests | In October, the company dosed in the Phase 2 PENINSULA (PrevENtIoN of IllnesS DUe to InfLuenza A) trial evaluating VIR-2482 for the prevention of illness due to influenza A. |
Competitor Comparison
| Key Parameters | Vir Biotechnology Inc | Kymera Therapeutics Inc | Viela Bio Inc | Finch Therapeutics Group Inc | AlloVir Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | San Francisco | Watertown | Gaithersburg | Boston | Waltham |
| State/Province | California | Massachusetts | Maryland | Massachusetts | Massachusetts |
| No. of Employees | 587 | 187 | 170 | 18 | 112 |
| Entity Type | Public | Public | Private | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Vicki Sato | Chairman | Executive Board | 2016 | 74 |
| Marianne De Backer | Chief Executive Officer; Director | Executive Board | 2023 | 54 |
| Sung Lee | Chief Financial Officer; Executive Vice President | Senior Management | 2023 | 52 |
| Johanna Friedl-Naderer | Chief Operating Officer; Executive Vice President | Senior Management | 2022 | - |
| Aine Hanly | Chief Technology Officer; Executive Vice President | Senior Management | 2021 | 53 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward